Cancer Genetics (CGIX) Reports Q3 EPS of $0.98 (Earlier)

Cancer Genetics (NASDAQ: CGIX) reported Q3 EPS of $0.98, versus ($9.34) reported last year. Revenue for the quarter came in at $2.1 million, versus $535 thousand reported last year.

For earnings history and earnings-related data on Cancer Genetics (CGIX) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• DeFi Technologies (DEFT) PT Lowered to $1 at Benchmark Following Q2 Miss
• Cummins wins battery storage contract for U.S. data center project